Merck & Co. & Moderna

Merck & Co.: Merck co-developed the vaccine and provided Pembrolizumab. The positive results expand its cancer portfolio and could offset future patent losses on Pembrolizumab. Merck's shares rose about 11%.

Moderna: Moderna is the co-developer of the vaccine and the primary beneficiary, with its stock more than doubling and adding about $40 billion in market value. The trial success validates its mRNA platform and could lead to a new revenue stream, helping the company return to profitability.

Merck & Co.: As the manufacturer of pembrolizumab (Keytruda), Merck & Co.>>> benefits from the combination therapy's success, as it reinforces the drug's role as a standard of care and expands its potential market in combination with intismeran. The positive results could lead to continued strong sales for pembrolizumab.

Moderna: As the manufacturer of intismeran, Moderna>>> is a key beneficiary of the positive clinical trial results, which could lead to increased revenue and market share in cancer treatment. The success of intismeran validates Moderna>>>'s mRNA vaccine platform for oncology applications.

Merck & Co.: Merck & Co. is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.

Moderna: Moderna is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.

Merck & Co.: Merck & Co.'s approved vaccine Ervebo for the Zaire strain of Ebola is referenced as a technological precedent for IAVI's Bundibugyo vaccine candidate.

Moderna: Moderna received up to $50 million from CEPI to support the preclinical and early clinical development of its mRNA-based Ebola Bundibugyo vaccine candidate, leveraging its mRNA platform for rapid response.

Merck & Co.: Merck & Co.>>>'s Ervebo vaccine, effective against the Zaire strain of Ebola, is being considered for potential use against the Uganda — Bundibugyo strain, though its efficacy is still under assessment.

Moderna: Moderna is one of the entities developing an experimental vaccine for the Bundibugyo virus, which could lead to future revenue and enhance its reputation in vaccine development.

Merck & Co.: Merck jumped 9.7% following the positive cancer vaccine data, boosting its outlook.

Moderna: Soared 150% on positive vaccine trial results, a notable market mover.